Transgenic Group Company Description

Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan.

It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services.

It also offers drug efficiency and pharmacological test and safety studies; sugar chain analysis and synthesis services; advice and support services, including M&A, business revitalization, business succession services; and contract production services, such as genetically modified mice, antibodies, protein hypers, and expressing cells, as well as sells mouse-related products and mouse models, and research reagents.

In addition, the company offers support service, including business succession and business revitalization, business succession, and investment business consultancy services.

The company was formerly known as Trans Genic Inc. and changed its name to Transgenic Group Inc. in October 2024.

Transgenic Group Inc. was incorporated in 1998 and is headquartered in Fukuoka City, Japan.

Transgenic Group Inc.

Country	Japan
Founded	1998
Industry	Biotechnology
Sector	Healthcare
Employees	241
CEO	Kenji Fukunaga

Contact Details

Address: 2-3-36 Tenjin Fukuoka City, 810-0001 Japan
Phone	81 9 2288 8470
Website	transgenic-group.co.jp

Stock Details

Ticker Symbol	2342
Exchange	Tokyo Stock Exchange
Stock Type	Common Stock
Fiscal Year	April - March
Reporting Currency	JPY
ISIN Number	JP3635720000
SIC Code	0200

Key Executives

Name	Position
Kenji Fukunaga	Chief Executive Officer
Kazuo Watanabe	Chief Financial Officer
Yutaka Funabashi	Head of Investor Relations